PreveCeutical Closes Initial Tranche of Non-Brokered Private Placement
Vancouver, British Columbia--(Newsfile Corp. - May 12, 2026) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H0) (the "Company" or "PreveCeutical"), is pleased to announce that, further to its news release dated April 22, 2026, it has closed an initial tranche (the "Initial Tranche") of its previously announced $1,000,000 non-brokered private placement (the "Offering"), which Initial Tranche consisted of the issuance of 13,600,000 units (e
Biotechnology, Pharmaceuticals, Health
2026-05-12 5:02 PM EDT | PreveCeutical Medical Inc.
DIMERx Preclinical Data Confirms DMX-101 Non-Addictive Profile: No Reinforcement, No Dependence
San Francisco, California--(Newsfile Corp. - May 12, 2026) - DIMERx, Inc. ("DIMERx" or "the Company") is a clinical-stage biopharmaceutical company dedicated to addressing the public-health crisis of drug misuse and dependence, with a portfolio of first-
Biotechnology, Pharmaceuticals, Health
2026-05-12 9:00 AM EDT | DIMERx INC.
BioHarvest Sciences Signs $1.2M CDMO Stage 2 Contract for the Development of a Rare Fragrance Using Its Proprietary Botanical Synthesis Platform
British Columbia and Rehovot, Israel--(Newsfile Corp. - May 12, 2026) - BioHarvest Sciences Inc. (NASDAQ: BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a leader in Botanical Synthesis technology and sustainable plant-based molecule development, today announced that its CDMO division has s
Biotechnology, Pharmaceuticals, Health
2026-05-12 7:30 AM EDT | BioHarvest Sciences Inc.
Phio Pharmaceuticals Announces "Innovations in Skin Cancer Treatment and Prevention" in a Fireside Chat with Force Family Office on Tuesday, May 19, 2026
King of Prussia, Pennsylvania--(Newsfile Corp. - May 12, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing tec
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2026-05-12 7:00 AM EDT | Phio Pharmaceuticals Corp.
Zenith Capital Corp. Amends Promissory Notes
Calgary, Alberta--(Newsfile Corp. - May 12, 2026) - Zenith Capital Corp. ("Zenith" or the "Company") today announces the amendment of an aggregate amount of US$11.1 million and CAD$6.7 million of promissory notes (the "Notes") held by an immediate family member (the "Lender") of Zenith's Chairman and CEO and entities controlled by the Lender to: (i) increase the interest rate for all Notes from 11% to 18% per annum, commencing effective February 1, 2026, (ii) to grant the Lender conversion pr
2026-05-12 12:40 AM EDT | Zenith Capital Corp.
Resverlogix Announces One-Year Extension of Debenture
Calgary, Alberta--(Newsfile Corp. - May 11, 2026) - Resverlogix Corp. (TSX: RVX) ("Resverlogix" or the "Company") announced today a one-year extension of the Company's US$6.0 million secured debenture with Shenzhen Hepalink Pharmaceutical Group Co., Ltd. ("Hepalink") (and payment of accrued interest thereon), extending the maturity date to May 13, 2027. In connection with the extension, the interest rate has been amended from 18% to 20% per annum, commencing on May 14, 2026. "
Technology, Biotechnology, Healthcare and Hospitals
2026-05-11 5:15 PM EDT | Resverlogix Corp.
Envoy Medical Reports Landmark Accomplishments, Advancing Toward FDA Approval of First-of-Its-Kind Fully Implanted Cochlear Implant
White Bear Lake, Minnesota--(Newsfile Corp. - May 11, 2026) - Envoy Medical® Inc. (NASDAQ: COCH) ("Envoy Medical" or the "Company"), a hearing health company pioneering fully implanted hearing solutions, today reported first quarter 2026 results and landmark achievements that advance the Company another step closer toward commercialization of its investigational Acclaim® cochlear implant. "The first quarter of 2026 marked a transformative period for Envoy Medical, highlighted
Biotechnology, Healthcare and Hospitals
2026-05-11 8:00 AM EDT | Envoy Medical, Inc.
American Aires Inc. Announces Updates on Annual Filings, Litigation and Listing Matters, Cease Trade Order, and 2024 Financial Statements
Toronto, Ontario--(Newsfile Corp. - May 8, 2026) - American Aires Inc. (CSE: WIFI) (OTC Pink: AAIRF) (the "Company") announces that further to the Company's news releases dated April 7, 2026 and April 17, 2026, it will not file its audited annual financial statements for the fiscal year ended December 31, 2025, together with the related management's discussion and analysis and CEO and CFO certifications (collectively, the "Required Filings"), because the audited financial statem
2026-05-08 6:00 PM EDT | American Aires Inc.
Kiora Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Corporate Update
Encinitas, California--(Newsfile Corp. - May 8, 2026) - Kiora Pharmaceuticals (NASDAQ: KPRX) today reported financial results for the first quarter ended March 31, 2026, and provided an update on its clinical pipeline of small molecules for the treatment of retinal diseases. First Quarter 2026 and Recent Highlights Enrollment in the Phase 2 ABACUS-2 study of KIO-301 remains very active, with expansion of clinical trial sites to accommodat
Biotechnology, Pharmaceuticals
2026-05-08 7:00 AM EDT | Kiora Pharmaceuticals, Inc.
Phio Pharmaceuticals Reports First Quarter 2026 Financial Results and Business Update
King of Prussia, Pennsylvania--(Newsfile Corp. - May 7, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio today reported its financial results for the quarter ended March 31, 2026, and provided a busine
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2026-05-07 4:05 PM EDT | Phio Pharmaceuticals Corp.
InMed Reports Third Quarter Fiscal 2026 Financial Results and Provides Business Update
Vancouver, British Columbia--(Newsfile Corp. - May 6, 2026) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today reports financial results for the third quarter of the fiscal year 2026 which ended March 31, 2026. The Company's full financial statements and related MD&A for the third
Biotechnology, Pharmaceuticals
2026-05-06 6:00 PM EDT | InMed Pharmaceuticals
Nextleaf Reports AGM Results and Expands Industry Leadership Through CCBC
Vancouver, British Columbia--(Newsfile Corp. - May 6, 2026) - Nextleaf Solutions Ltd. (CSE: OILS) (OTCQB: OILFF) (FSE: L0MA) ("Nextleaf", "OILS", or the "Company"), a multi-patented life science company and Canadian cannabis processor announces the results of its annual general meeting of shareholders (the "Meeting") held on April 30, 2026, in Vancouver, British Columbia, and provides an update on its continued engagement in industry advocacy initiatives supporting the advancement of B
Biotechnology, Pharmaceuticals, Cannabis, Cannabis Extractor
2026-05-06 9:00 AM EDT | Nextleaf Solutions Ltd.
Theralase(R) Announces $4 Million Brokered LIFE Offering
Toronto, Ontario--(Newsfile Corp. - May 5, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to the research and development of energy-activated small molecules for the safe and effective destruction of cancer, bacteria and v
Technology, Biotechnology, Healthcare and Hospitals, Pharmaceuticals
2026-05-05 7:10 PM EDT | Theralase Technologies Inc.
Illumisoft Lighting Corp. Provides Corporate Update Following Commencement of Trading
Vancouver, British Columbia--(Newsfile Corp. - May 5, 2026) - Illumisoft Lighting Corp. (TSXV: UVC) (the "Company" or "Illumisoft"), a Canadian public company commercializing UV-based air disinfection technologies and a leading portfolio of energy efficient commercial LED lighting products, today provided the following corporate update. TSX-V Listing and Public Company Platform On April 23, 2026, Illumisoft Lighting Corp. commenced trading on the TSX Venture Exchange
Technology, Biotechnology, Healthcare and Hospitals, Household / Consumer / Cosmetics
2026-05-05 9:16 AM EDT | Illumisoft Lighting Corp.
Breathe BioMedical Expands Multi-Center Clinical Study in Breast Cancer to Pittsburgh
New Brunswick and Cambridge, Massachusetts--(Newsfile Corp. - May 5, 2026) - Breathe BioMedical, a company developing a breath analytics platform for early disease detection, today announced the addition of Weinstein Imaging Associates in Pittsburgh, Pennsylvania as a new clinical site in its large multi-center observational collection protocol study to advanc
Technology, Biotechnology, Healthcare and Hospitals, Health
2026-05-05 9:00 AM EDT | Breathe BioMedical Inc.
Therma Bright Announces Follow-On Order from Horizon Health as Venowave(TM) Gains Traction in U.S. Vascular Markets
Toronto, Ontario--(Newsfile Corp. - May 5, 2026) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) (FSE: JNX0) ("Therma" or the "Company"), a developer and investment partner specializing in advanced medical device technologies, is pleased to announce that Horizon Health ("Horizon") has purchased an additional 100 Venowave™ units. This second commercial order follows the rapid deployment and clinical success of the initial 100-unit shipment delivered to Horizon in la
Technology, Biotechnology, Health
2026-05-05 6:30 AM EDT | Therma Bright Inc.
Bachem Announces Changes to the Corporate Executive Committee
Bubendorf, Switzerland--(Newsfile Corp. - May 5, 2026) - Bachem Holding AG (SIX: BANB) (“Bachem”) today announced that Torsten Wöhr, Chief Commercial Officer, has decided to pursue a new opportunity outside the company. Until a successor will be appointed, Anne-Kathrin Stoller will assume the role of Chief Commercial Officer in addition to her responsibilities as Chief Executive Officer (CEO), effective May 25, 2026. “Torsten Wöhr
Biotechnology, Chemical, Healthcare and Hospitals, Pharmaceuticals
2026-05-05 1:08 AM EDT | Bachem Holding AG
Scryb Inc. Changes Name to NorthPalm Capital Corp. and Announces New Trading Symbols
Toronto, Ontario--(Newsfile Corp. - May 4, 2026) - NorthPalm Capital Corp. (CSE: NP) ("NorthPalm Capital" or the "Company") (formerly, Scryb Inc.), is pleased to announce that further to its news release dated April 15, 2026, the Company's common shares will commence trading on the Canadian Securities Exchange under the new name, "NorthPalm Capital Corp." effective at the market open on May 7, 2026 (the "Name Change") and the trading symbol for the Company will cha
Biotechnology, Healthcare and Hospitals, Health
2026-05-04 9:41 PM EDT | NorthPalm Capital Corp.
Theralase(R) Releases 2025 Annual Financial Statements and Provides Clinical Study Update
Toronto, Ontario--(Newsfile Corp. - May 4, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to the research and development of energy-activated small molecules for the safe and effective destruction of various cancer, bacteria and viruses has released the Company's audited consolidated financial statements for the twelve-month period ended December 31
Technology, Biotechnology, Healthcare and Hospitals, Pharmaceuticals
2026-05-04 5:22 PM EDT | Theralase Technologies Inc.
Neural Therapeutics Announces Filing and Mailing of Meeting Materials for Annual and Special Meeting to Approve Series B Transactions with CWE
Toronto, Ontario--(Newsfile Corp. - May 1, 2026) - Neural Therapeutics Inc. (CSE: NURL) (FSE: HANF) ("Neural" or the "Company"), an ethnobotanical drug discovery company focused on developing therapeutic solutions for mental health conditions related to substance use disorders, announces that it has filed on SEDAR+ and completed the mailing of its notice of annual and special meeting, management information circular and related meeting materials (collectively, the "Mee
Biotechnology, Pharmaceuticals, Health, Psychedelics
2026-05-01 8:04 AM EDT | Neural Therapeutics Inc.